Phase II clinical study of pirarubicin in hormone resistant prostate cancer

Abstract

Twenty one patients with hormone resistant prostate cancer were entered in a phase II study of pirarubicin 70 mg/m2, as a single intravenous injection given at 21 day intervals. All patients had leukopenia (9 severe or life threatening) and 2 died of septicemia. Thrombocytopenia occurred in 5 patients (one life threatening) and anemia in 12 patients. One partial response of 3 months duration was documented. Pirarubicin 70 mg/m2 given intravenously at 21 day intervals causes severe hematological toxicity and has minimal therapeutic activity in patients with hormone resistant prostate cancer.

DOI: 10.1007/BF00873129

2 Figures and Tables

Statistics

050010001500'96'98'00'02'04'06'08'10'12'14'16
Citations per Year

498 Citations

Semantic Scholar estimates that this publication has 498 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Rapoport1992PhaseIC, title={Phase II clinical study of pirarubicin in hormone resistant prostate cancer}, author={Bernardo Rapoport and Geoffrey Falkson}, journal={Investigational New Drugs}, year={1992}, volume={10}, pages={119-121} }